Xelenka
Xelenka
Venable’s BiologicsHQ Monthly Injection – December 2023
Damineh Morsali, Ph.D.; Monica Chou; Robert S. Schwartz, Ph.D.
January 13, 2024
Subscribe Now For Future Updates
Related Articles
- The State of Biosimilars in 2023
- Supreme Court Affirms Lack of Enablement in Amgen v. Sanofi Antibody Patent Dispute
- First Humira Biosimilar Enters the U.S. Market
- What Do the Humira Biosimilar / Interchangeable Launches Mean for the Adalimumab Market?
- BPCIA Litigation Related to Proposed Eylea Biosimilar CT-P42 Filed
- EYLEA® (aflibercept) IPR and BPCIA Litigation Updates
- New FDA Guidance Removes Interchangeability Statement from Product Labels
- First List of Drugs for Medicare Price Negotiations Published Includes Three Biologics
- Senators Tillis and Coons Reintroduce Patent Eligibility Reform Legislation
- PREVAIL Act Reforms at the PTAB
- PTAB Eliminates POP Review and Expands Director Review to Institution Decisions
- Celltrion Completes Application for FDA Approval of CT-P41, Biosimilar of Prolia® / Xgeva®
- EYLEA® (aflibercept) and Soliris® (eculizumab) IPR and BPCIA Litigation Updates
- Spotlight On: Actemra® (tocilizumab) / Tofidence™ (tocilizumab-bavi) / Tyenne® (tocilizumab-aazg)
- Spotlight On: Biosimilar Litigations
- Spotlight On: Enbrel® (etanercept) / Erelzi® (etanercept-szzs) / Eticovo® (etanercept-ykro)
- Spotlight On: Herceptin® (trastuzumab) / Ogivri® (trastuzumab-dkst) / Herzuma® (trastuzumab-pkrb) / Ontruzant® (trastuzumab-dttb) / Trazimera® (trastuzumab-qyyp) / Kanjinti® (trastuzumab-anns) / Hercessi™ (trastuzumab-strf)
- Spotlight On: Humira® (adalimumab) / Amjevita™ (adalimumab-atto) / Cyltezo® (adalimumab-adbm) / Hyrimoz™ (adalimumab-adaz) / Hadlima™ (adalimumab-bwwd) / Abrilada™ (adalimumab-afzb) / Hulio® (adalimumab-fkjp) / Yusimry™ (adalimumab-aqvh) / Idacio® (adalimumab-aacf) / Yuflyma® (adalimumab-aaty) / Simlandi® (adalimumab-ryvk)
- Spotlight On: Lantus® / Lantus® SoloSTAR® (insulin glargine recombinant) / Basaglar® (insulin glargine) / Semglee® (insulin glargine) / Rezvoglar™ (insulin glargine-aglr)
- Spotlight On: Neulasta® (pegfilgrastim) / Fulphila® (pegfilgrastim-jmdb) / Udenyca® (pegfilgrastim-cbqv) / Ziextenzo® (pegfilgrastim-bmez) / Nyvepria®(pegfilgrastim-apgf) / Fylnetra™ (pegfilgrastim-apgf) / Stimufend® (pegfilgrastim-fpgk)
- Spotlight On: Rituxan® (rituximab) / Truxima® (rituximab-abbs) / Ruxience® (rituximab-pvvr) / Riabni™ (rituximab-arrx)
Current Topics
Abrilada
adalimumab
Amgen
Amjevita
Avastin
Basaglar
bevacizumab
Biologics
Biosimilars
BPCIA
Celltrion
Cyltezo
Enbrel
Erelzi
Etanercept
Eticovo
eylea
FDA
Federal Circuit
Filgrastim
Genentech
Hadlima
Herceptin
Herzuma
Humira
Hyrimoz
Insulin Glargine
IPR
Lantus
Litigation
Mylan
Neulasta
Neupogen
Patents
Pegfilgrastim
PGR
PTAB
Rituxan
rituximab
Ruxience
Samsung Bioepis
Sandoz
Supreme Court
Trastuzumab
Truxima